logo-loader

Circassia Pharmaceuticals PLC

Receive alerts
Market:
LSE
Market Cap:
£73.16 m
Price
19.50 GBX
Change
0.52%
52 weeks high
59.00
52 weeks low
13.25

In brief

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. We are expanding our commercial platform in China, and are working to expand our portfolio through in-licensing, partnering or acquisition. 

https://www.circassia.com/company/

Deep dive We explore the investor case for growth companies

Snapshot

  • Specialty pharma group focused on respiratory diseases
  • Growing revenue base; set its sights on profitability
  • New product launch will be pivotal to those aspirations

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Neil Woodford's fall from grace: Where it went wrong for the famed stock-picker

Woodford has made some bad investment calls: Provident Financial, Capita, Circassia Pharmaceuticals and Allied Minds

on 4/6/19